+1 (888) 794-0077
« Return

Ensure a Successful Clinical Translation with DMPK Strategies

DMPK – A Key Step, Every Step of the Way

Drug metabolism and pharmacokinetics (DMPK) is a crucial component in the success of your drug development – at every stage, from discovery to preclinical to clinical.

DMPK studies set basic expectations of drug behavior, which is necessary in order to move your current or upcoming project to first-in-human trials. Tune in to this webinar to get information and strategies to help you more quickly and efficiently do just that.

What You’ll Learn

In this webinar, Dr. Jing Jin*, head of WuXi AppTec’s DMPK Study Director team, discusses the DMPK screening roadmap, considerations when moving into clinical stages, strategies for the development of novel therapeutics, and what a successful IND application should include – with tips on what regulatory agencies may look for in future applications.

These topics will include the specifics of:

  • Desired dose regimen (dose level and frequency)
  • Balanced disposition pathways
  • No human-specific metabolites
  • Low drug-drug interaction potential
  • Minimal risk of forming reactive metabolites

Move your project forward faster.

*Dr. Jin Jing leads the DMPK Study Director Team at WuXi AppTec’s Shanghai, China location. With more than a decade of experience, Dr. Jin has applied his expertise in drug metabolism and pharmacokinetics at WuXi AppTec since 2016. Before joining the company, he was an investigator of Clinical Pharmacology at Novartis. Dr. Jin provides a wealth of knowledge about the DMPK drug development journey – from discovery to clinical, and is a frequent speaker on the subject. He received his B.S. in Biochemistry from Nanjing University and his Ph.D. in Pharmacology from Vanderbilt University.

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient, socially responsible and sustainable solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 4,100 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that “every drug can be made and every disease can be treated.”

For more information, please visit: https://labtesting.wuxiapptec.com/

Related Articles

The Advantages of LC-MS/MS in Optimizing ADC Bioassays

The Advantages of LC-MS/MS in Optimizing ADC Bioassays

Antibody-drug conjugates (ADCs) are offering hope to cancer patients worldwide. This novel treatment combines the precision targeting of antibodies with the cancer cell-killing power of cytotoxins, delivering treatments directly to tumors and minimizing damage to healthy tissues.